Arkopharma Sustainability Profile
Arkopharma, officially known as Arkopharma Pharmaceutical Industries, is a leading player in the natural health sector, headquartered in Carros, France. Founded in 1980, the company has established itself as a pioneer in the development of phytotherapy and dietary supplements, focusing on harnessing the power of nature to promote well-being. With a strong presence across Europe and beyond, Arkopharma offers a diverse range of products, including herbal medicines, vitamins, and minerals. Their commitment to quality and innovation is evident in their unique formulations, which combine traditional knowledge with modern scientific research. Recognised for their expertise, Arkopharma has achieved significant milestones, including numerous certifications that underscore their dedication to safety and efficacy in health solutions. As a trusted name in the industry, Arkopharma continues to lead the way in natural health, making a positive impact on consumers' lives.
DitchCarbon Score
How does Arkopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arkopharma's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arkopharma's reported carbon emissions
As of the latest available data, Arkopharma does not report specific carbon emissions figures, indicating a lack of detailed emissions data for the most recent year. The company is a current subsidiary of ARKOPHARMA Laboratories, Company Limited, and emissions data may be inherited from its parent company, Dermapharm Holding SE, at a cascade level of three. However, no specific emissions figures or reduction targets have been disclosed. Arkopharma has not established any documented reduction initiatives or commitments to the Science Based Targets initiative (SBTi), nor does it appear to have set any climate pledges. This absence of data suggests that while Arkopharma may be engaged in sustainability efforts, specific targets or achievements in carbon emissions reduction are not currently available. In the broader context of the industry, many pharmaceutical companies are increasingly focusing on sustainability and carbon neutrality, often setting ambitious targets to reduce their carbon footprints. Arkopharma's current lack of publicly available emissions data and reduction commitments may reflect an opportunity for the company to enhance its climate strategy and align with industry standards.
How Carbon Intensive is Arkopharma's Industry?
How Carbon Intensive is Arkopharma's Location?
Arkopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Arkopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.